ACCEL Subscription

Convenient Solutions. Relevant to Your Entire Care Team.

A proud part of the American College of Cardiology’s distinguished educational portfolio, ACCEL is the premier cardiovascular audio journal, carefully and intuitively designed to help you stay current and meet all your learning needs.

ACCEL provides direct access to the researchers who share backstories and perspective that is unlike any other product. It includes actionable content that’s highly relevant to not only physicians, but today’s comprehensive cardiovascular care team — and translates directly into improved patient care. You will be able to implement new learnings in real–world practice, access convenient, on-the-go cardiovascular education, and stay up–to–date with the latest and greatest in the ever-expanding field of cardiology.

This audio journal delivers short, CME-certified interviews, revealing insights beyond the published data that only conversations between experts could uncover. These vital updates from key cardiology conferences and subspecialty conferences are all available whenever and wherever you choose.

This engaging content includes new interviews and insider discussions with more than 120 leading medical institutions covering current, clinically relevant, evidence-based information, insight, and updates. Each interview is accompanied by a detailed written summary, complete with educational objectives, faculty disclosures acknowledgements, suggested readings, knowledge assessment tests, and evaluation questions.

Each interview qualifies for AMA PRA Category 1 Credits™ and ABIM Part II Maintenance of Certification (MOC) Points (Nov 2016 and newer issues).

Hot Topics Interviews
Check out these FREE ACCEL interviews on the hottest topics in the field.

EVAPORATE: The Final Results
Matthew J. Budoff, MD, FACC, Professor of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA

Interviewer: Vinod H. Thourani, MD, FACC, Marcus Chief of Cardiovascular Surgery, Marcus Heart Valve Center and Piedmont Heart Institute, Atlanta, GA
Correspondent: Poonam Velagapudi, MD, MS, FACC, Assistant Professor of Medicine, University of Nebraska Medical Center, Omaha, NE

This groundbreaking study’s data, now being released for the first time, demonstrate plaque regression in response to icosapent ethyl.

New Treatments for an Old Disease: SGLT2i in Heart Failure
Javed Butler, MBBS, MPH, MBA, FACC, Professor and Chair, Department of Medicine, University of Mississippi Medical Center, Jackson, MS

Interviewer: Alison L. Bailey, MD, FACC, FAACVPR, Chief of Cardiology, Centennial Heart at Parkridge HCA Healthcare, Chattanooga, TN

Patients with HF have a high risk of adverse outcomes and need novel therapies beyond the current standard of care. EMPEROR REDUCED looked at higher-risk HFrEF patients (with lower EF and high NT-proBNP) to assess the benefits of SGLT2 inhibition.

EMPEROR REDUCED showed a reduction in the primary outcome with the SGLT2 inhibitor empagliflozin in patients with HF with or without diabetes mellitus.